201 related articles for article (PubMed ID: 29386247)
41. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
[TBL] [Abstract][Full Text] [Related]
42. Prognostic relevance of androgen receptor detection in operable breast cancer.
Søiland H; Kørner H; Skaland I; Janssen EA; Gudlaugsson E; Varhaug JE; Baak JP; Søreide JA
J Surg Oncol; 2008 Dec; 98(7):551-8. PubMed ID: 18937259
[TBL] [Abstract][Full Text] [Related]
43. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
44. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
[TBL] [Abstract][Full Text] [Related]
45. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
[TBL] [Abstract][Full Text] [Related]
46. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
[TBL] [Abstract][Full Text] [Related]
47. Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
Elebro K; Bendahl PO; Jernström H; Borgquist S
Breast Cancer Res Treat; 2017 Oct; 165(3):645-657. PubMed ID: 28643022
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
49. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
50. Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
Niméus E; Folkesson E; Nodin B; Hartman L; Klintman M
Anticancer Res; 2017 Dec; 37(12):6845-6853. PubMed ID: 29187464
[TBL] [Abstract][Full Text] [Related]
51. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
52. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
[TBL] [Abstract][Full Text] [Related]
53. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
54. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.
Hall RE; Clements JA; Birrell SN; Tilley WD
Br J Cancer; 1998 Aug; 78(3):360-5. PubMed ID: 9703283
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
56. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
58. Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.
Jinna ND; Van Alsten S; Rida P; Seewaldt VL; Troester MA
Breast Cancer Res Treat; 2023 Sep; 201(2):171-181. PubMed ID: 37438515
[TBL] [Abstract][Full Text] [Related]
59. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
60. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
Erber R; Angeloni M; Stöhr R; Lux MP; Ulbrich-Gebauer D; Pelz E; Bankfalvi A; Schmid KW; Walter RFH; Vetter M; Thomssen C; Mayr D; Klauschen F; Sinn P; Sotlar K; Stering K; Stenzinger A; Wunderle M; Fasching PA; Beckmann MW; Hoffmann O; Kimmig R; Harbeck N; Wuerstlein R; Ferrazzi F; Hartmann A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
